Clinical Trial Update: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial of Fitusiran in severe Hemophilia A and B patients without inhibitors completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fitusiran (fitusiran)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hemophilia A, Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2022-02-04